Gezielt nachschlagen
Suche
Suche startet nach einer kurzen Eingabepause.
20 angezeigte Treffer · Seite 2, keine Gesamtzahl für „upadacitinib“
Suchtreffer
Begriffe & Kennungen
Rinvoq · 4.8 · 79 • Total cholesterol ≥ 5.17 mmol/L (200 mg/dL): 49% vs. 11%, in the upadacitinib 45 mg and placebo groups, r
Eintrag öffnenRinvoq · 4.8 · 80 section 4.2). No notable mean changes of lymphocyte counts were observed during upadacitinib treatment over
Eintrag öffnenRinvoq · 4.8 · Elevations in lipid parameters were observed at 8 weeks of treatment with upadacitinib 45 mg and remained gene
Eintrag öffnenRinvoq · 4.8 · Elevations in lipid parameters were observed at 8 weeks of treatment with upadacitinib 45 mg and remained gene
Eintrag öffnenRinvoq · 4.8 · In placebo-controlled clinical studies, the frequency of serious infection over 16 weeks in the upadacitinib 1
Eintrag öffnenRinvoq · 4.8 · In placebo-controlled clinical studies, the frequency of serious infection over 16 weeks in the upadacitinib 1
Eintrag öffnenRinvoq · 4.8 · In the placebo-controlled induction studies over 8 weeks, the frequency of herpes zoster in the upadacitinib 4
Eintrag öffnenRinvoq · 4.8 · In the placebo-controlled induction studies over 8 weeks, the frequency of herpes zoster in the upadacitinib 4
Eintrag öffnenRinvoq · 4.8 · In the placebo-controlled induction studies, the frequency of infection over 8 weeks in the upadacitinib 45 mg
Eintrag öffnenRinvoq · 4.8 · In the placebo-controlled induction studies, the frequency of infection over 8 weeks in the upadacitinib 45 mg
Eintrag öffnenRinvoq · 4.8 · Overall, the safety profile observed in patients with Crohn’s disease treated with upadacitinib was consistent
Eintrag öffnenRinvoq · 4.8 · Overall, the safety profile observed in patients with Crohn’s disease treated with upadacitinib was consistent
Eintrag öffnenRinvoq · 4.8 · Overall, the safety profile observed in patients with active axial spondyloarthritis treated with upadacitinib
Eintrag öffnenRinvoq · 4.8 · Overall, the safety profile observed in patients with active axial spondyloarthritis treated with upadacitinib
Eintrag öffnenRinvoq · 4.8 · Overall, the safety profile observed in patients with active psoriatic arthritis treated with upadacitinib 15
Eintrag öffnenRinvoq · 4.8 · Overall, the safety profile observed in patients with active psoriatic arthritis treated with upadacitinib 15
Eintrag öffnenRinvoq · 4.8 · Overall, the safety profile observed in patients with giant cell arteritis treated with upadacitinib 15 mg was
Eintrag öffnenRinvoq · 4.8 · Overall, the safety profile observed in patients with giant cell arteritis treated with upadacitinib 15 mg was
Eintrag öffnenRinvoq · 4.8 · The long-term rate of herpes zoster for the upadacitinib 15 mg group across all five Phase 3 clinical studies
Eintrag öffnenRinvoq · 4.8 · The long-term rate of herpes zoster for the upadacitinib 15 mg group across all five Phase 3 clinical studies
Eintrag öffnen